Codeine 60mg tablets

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Codeine phosphate

Pieejams no:

Sandoz Ltd

ATĶ kods:

R05DA04

SNN (starptautisko nepatentēto nosaukumu):

Codeine phosphate

Deva:

60mg

Zāļu forma:

Oral tablet

Ievadīšanas:

Oral

Klase:

Schedule 5 (CD Inv)

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 04070200

Lietošanas instrukcija

MEASURE BAR SHOULD BE 150MM AT 100% SCALE
Customer
Description
Item Code
Profile
Size
Min. Point Size
Market
Language
Proof By
Proof No.
Date
Artwork No.
Pharma
Code
Colours Used
Wockhardt UK Limited
Codeine Phosphate Weifa leaflet
107021/3
n-a
206 x 336mm
matt.pirie-scott
1
21/04/2015
569101
404
Process Black
Keylines (Does not print)
Text Limit
[e-mail]
CLEARLY MARK ANY AMENDMENTS ON ONE PROOF AND RETURN TO MPS
WARNING! We cannot accept responsibility for any errors
in this proof after approval. Whilst we take extreme care
at all times to ensure accuracy to our clientʼs brief,
the final responsibility must be taken by our client.
IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING
FULL APPROVAL OF DESIGN AND TEXT.
UK
English
9.3pt (main body) / 9.3pt (variables)
PACKAGE LEAFLET: INFORMATION FOR THE USER
CODEINE PHOSPHATE TABLETS
Read all of this leaflet carefully before you start using this
medicine.
– Keep this leaflet. You may need to read it again.
–
If you have further questions, please ask your doctor, nurse or
pharmacist.
–
This medicine has been prescribed for you personally and you should
not pass it on to others. It may harm them, even if their symptoms are
the same as yours.
–
If any of the side effects gets serious, or if you
notice any side effects not listed in this leaflet,
please tell your doctor, nurse or pharmacist.
In this leaflet:
1.
What Codeine Phosphate Tablets are and what
they are used for
2.
Before you take Codeine Phosphate Tablets
3. How Codeine Phosphate Tablets should be taken
4. Possible side effects
5. How to store Codeine Phosphate Tablets
6. Further information
1.
WHAT CODEINE PHOSPHATE TABLETS ARE AND WHAT THEY ARE
USED FOR
This product contains codeine. Codeine belongs to a group of medicines
called opioid analgesics which act to relieve pain. It can be used on
its
own or in combination with other pain killers such as paracetamol.
Codeine can be used in children over 12 years of age for the
short-term
relief of moderate pain that is not relieved by other p

Produkta apraksts

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Codeine Phosphate Tablets 60mg.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains codeine phosphate BP 60mg.
3.
PHARMACEUTICAL FORM
Tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
As an analgesic in mild to moderate pain, as an anti-tussive, and for
the
symptomatic treatment of chronic diarrhoea.
Codeine is indicated for the treatment of acute moderate pain which is
not
considered to be relieved by other analgesics such as paracetamol or
ibuprofen
(alone).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Codeine Phosphate Tablets 60 mg are not indicated for children 0-18
years
old.
Codeine should be used at the lowest effective dose for the shortest
period of
time. This dose may be taken, up to 4 times a day at intervals of not
less than 6
hours. Maximum daily dose of codeine should not exceed 240 mg.
In mild to moderate pain:
Adults and the elderly:
30 mg to 60 mg every 6 hours when necessary, to a
maximum of 180 mg daily.
As an anti-tussive:
Adults and the elderly:
15 mg to 30 mg, 3 or 4 times daily.
For the symptomatic treatment of chronic diarrhoea:
Adults and the elderly:
15 mg to 60 mg every 6 hours, to a maximum of 180 mg
daily.
The duration of treatment should be limited to 3 days and if no
effective pain
relief is achieved the patients/carers should be advised to seek the
views of a
physician.
Method of administration: Oral.
4.3
CONTRAINDICATIONS
•
Respiratory depression and liver failure.
•
In all paediatric patients (0-18 years of age) who undergo
tonsillectomy and/or adenoidectomy for obstructive sleep apnoea
syndrome due to an increased risk of developing serious and life-
threatening adverse reactions (see section 4.4).
•
In women during breastfeeding (see section 4.6).
•
In patients for whom it is known they are CYP2D6 ultra-rapid
metabolisers.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Prolonged use of high doses has produced morphine-like dependency.
Avoid
when there is a history of asthma, hepatic or